Biogen's earnings report indicates challenges with weak guidance and declining key drug franchises, which are critical for future growth. The poor performance of Leqembi and lack of promising pipeline products further contribute to a negative outlook. The decline in the multiple sclerosis franchise and minimal impact from new drug approvals suggest limited growth potential, likely leading to a negative short-term impact on Biogen's stock price.